EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair Md

ONCOLOGY · 2025

DOI: 10.46883/2025.25921053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ONCOLOGY, 2025. Verfasst von Wael Abdulla Moh Khair Md. Hauptthemen laut MEDLINE: Hodgkin Disease, Positron-Emission Tomography, Antineoplastic Combined Chemotherapy Protocols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interim fluorodeoxyglucose (FDG)-PET is currently the most used predictor of early response to treatment in advanced-stage Hodgkin lymphoma. Patients with a negative PET after 2 cycles of chemotherapy (PET2) have a better treatment outcome than their counterparts. The objective of this review was to assess how PET-adapted treatment approaches have enhanced the management of advanced-stage Hodgkin lymphoma by adapting treatment according to initial response. PubMed, Web of Science, ScienceDirect, Google Scholar, Scopus, and the Cochrane Library were systematically searched using randomized controlled trials, phase 2/3 clinical trials, and systematic reviews between 2000 and 2024. Keywords used were "Hodgkin lymphoma," "PET-adapted treatment," "ABVD," "BEACOPP," "interim PET," and "treatment escalation/de-escalation." PET-adapted treatment strategies decrease PET2-negative patient treatment, decreasing adverse effects with no reduction in effectiveness, as evidenced by the RATHL, AHL2011, and HD18 trials. In PET2-positive patients, trials such as SWOG S0816 and HD0607 prove that the early intensification of treatment improves survival. Novel treatments, such as brentuximab vedotin and nivolumab, are promising options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseasePositron-Emission TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm StagingFluorodeoxyglucose F18DoxorubicinBleomycinVincristineDacarbazineVinblastineCyclophosphamidePrednisone

Substanzen

Fluorodeoxyglucose F18DoxorubicinBleomycinVincristineDacarbazineVinblastineCyclophosphamidePrednisone

Zitieren

APA

Wael Abdulla Moh Khair Md (2025). Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era. ONCOLOGY. https://doi.org/10.46883/2025.25921053

Vancouver

Wael Abdulla Moh Khair Md. Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era. ONCOLOGY. 2025. doi:10.46883/2025.25921053

BibTeX
@article{WaelAbdullaMohKhairMd2025,
  author = {Wael Abdulla Moh Khair Md},
  title = {Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era},
  journal = {ONCOLOGY},
  year = {2025},
  doi = {10.46883/2025.25921053}
}
Kostenlos starten →